High rates of 30-day mortality in patients with cirrhosis and COVID-19Massimo Iavarone, Pietro Lampertico, Roberta D’Ambrosio et al.|Journal of Hepatology|2020Cited by 394
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis CRoberta D’Ambrosio, S. Fagiuoli, P. Del Poggio et al.|Journal of Hepatology|2018Cited by 133
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failureElisabetta Degasperi, S. Fagiuoli, Angiola Spinetti et al.|Journal of Hepatology|2019Cited by 92
Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohortAlessandro Soria, G. Aimo, Marco Fava et al.|Liver International|2020Cited by 19
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life studyRoberta D’Ambrosio, S. Fagiuoli, L. Pasulo et al.|Digestive and Liver Disease|2019Cited by 17